Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price dropped 22.9% during mid-day trading on Thursday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares traded hands during trading, a decline of 5% from the average daily volume of 530,419 shares. The stock had previously closed at C$0.24.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a fifty day moving average of C$0.18 and a 200-day moving average of C$0.11. The firm has a market capitalization of C$26.96 million, a P/E ratio of -5.39 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Want to Profit on the Downtrend? Downtrends, Explained.
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Buy P&G Now, Before It Sets A New All-Time High
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Canada Bond Market Holiday: How to Invest and Trade
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
